Inter Partes Review can potentially offer a more economical and streamlined litigation strategy for pharma and biotech players, writes David Dalke.
David Dalke
Advertisement
Articles by David Dalke
Advertisement
Latest Updated Articles
New Patent-Defense Path for PharmaOctober 1st 2014
Advertisement
Advertisement
Trending on PharmExec
1
The Impact That the Renewed Focus on Domestic Manufacturing Might Have on the Supply Chain
2
FDA Launches Rare Disease Framework Initiative
3
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
4
Vir Biotechnology Enters R&D Collaboration with Gilead for Three Novel PRO-XTEN Dual Masked T-Cell Engagers
5